{"id":13732,"date":"2009-10-05T08:21:06","date_gmt":"2009-10-05T08:21:06","guid":{"rendered":"https:\/\/www.ncf.de\/?post_type=avada_portfolio&#038;p=13732"},"modified":"2021-11-26T00:16:12","modified_gmt":"2021-11-26T00:16:12","slug":"cryo-save-gruppe","status":"publish","type":"avada_portfolio","link":"https:\/\/www.ncf.de\/en\/transaktion\/cryo-save-gruppe\/","title":{"rendered":"Cryo-Save Gruppe"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1270px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:calc( 0.026666666666667 * calc( 100% - 20px ) );--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><p>Network Corporate Finance advised the Executive Board of Cryo-Save Group N.V., based in Zutphen, the Netherlands, on the preparation and execution of its listing on NYSE Euronext Amsterdam, as well as on the evaluation of strategic options.<\/p>\n<div class=\"reference-data\">\n<p><strong>Transaction<\/strong><\/p>\n<p>In order to strengthen its capital market profile and attract new investors, Cryo-Save Group\u2019s shares, which were listed on the London Stock Exchange (AIM), were listed on NYSE Euronext Amsterdam. To this end, a 5:1 reverse share split was first carried out to consolidate the company\u2019s existing shares at a nominal value of EUR 0.10 per share, thereby meeting the listing requirements of NYSE Euronext. At the same time, the prospectus was drawn up and subsequently approved by the competent supervisory authority, Stichting Autoriteit Financi\u00eble Markten (\u201cAFM\u201d). The shares were admitted to trading on NYSE Euronext Amsterdam on 22 October 2009.<\/p>\n<p><strong>Target Company<\/strong><\/p>\n<p>As Europe\u2019s largest stem cell bank, the Cryo-Save Group specialises in the storage of stem cells from umbilical cord blood and umbilical cord tissue. Founded in 2000, the company pursues a growth strategy focused on international expansion and is now active in 38 countries. As of the end of 2009, it was managing more than 120,000 storage units.<\/p>\n<p><strong>Key Facts<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td>Transaction value:<\/td>\n<td>EUR 61 Mio.<\/td>\n<\/tr>\n<tr>\n<td>Sector:<\/td>\n<td>Medizinische Dienstleistungen<\/td>\n<\/tr>\n<tr>\n<td>Sales:<\/td>\n<td>EUR 37 Mio. (2009e)<\/td>\n<\/tr>\n<tr>\n<td>Employees:<\/td>\n<td>approx. 220<\/td>\n<\/tr>\n<tr>\n<td>Date:<\/td>\n<td>Oktober 2009<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>The role of Network Corporate Finance<\/strong><\/p>\n<p>Network Corporate Finance advised the client on the preparation and execution of the listing process and examined options for the company\u2019s strategic development.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Oktober 2009<br \/>\nNetwork hat den Vorstand der Cryo-Save Group bei der Vorbereitung und Durchf\u00fchrung des Listings an der NYSE Euronext Amsterdam sowie bei der Pr\u00fcfung strategischer Optionen beraten.<\/p>","protected":false},"author":4,"featured_media":16615,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":{"footnotes":""},"portfolio_category":[41,199,223],"portfolio_skills":[216],"portfolio_tags":[154],"class_list":["post-13732","avada_portfolio","type-avada_portfolio","status-publish","format-standard","has-post-thumbnail","hentry","portfolio_category-kapitalmarktberatung","portfolio_category-international","portfolio_category-ipo-beratung","portfolio_skills-kapitalmarktberatung","portfolio_tags-healthcare"],"_links":{"self":[{"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/avada_portfolio\/13732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/avada_portfolio"}],"about":[{"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/types\/avada_portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/comments?post=13732"}],"version-history":[{"count":1,"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/avada_portfolio\/13732\/revisions"}],"predecessor-version":[{"id":17699,"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/avada_portfolio\/13732\/revisions\/17699"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/media\/16615"}],"wp:attachment":[{"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/media?parent=13732"}],"wp:term":[{"taxonomy":"portfolio_category","embeddable":true,"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/portfolio_category?post=13732"},{"taxonomy":"portfolio_skills","embeddable":true,"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/portfolio_skills?post=13732"},{"taxonomy":"portfolio_tags","embeddable":true,"href":"https:\/\/www.ncf.de\/en\/wp-json\/wp\/v2\/portfolio_tags?post=13732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}